Daryl L. Thompson is an American inventor, entrepreneur, and biohacker known for his contributions to pharmaceutical and biological research through published papers,[1][2] works cited in the scientific community,[3] and multiple US patents.[4] Thompson's research focuses on the development of innovative therapeutic platforms for a wide range of applications, including metabolic, neurologic, cancer, and infectious diseases.
Since 2010, Thompson has served as President and Director of Scientific Initiatives at Global Research and Discovery Group (GRDG Sciences, LLC) in Winter Haven, FL, which is a private research and development organization. GRDG Sciences is a think tank that works to provide solutions to emerging global epidemics and pandemics.[5]
Thompson and GRDG have completed a 5-year comprehensive research project of highly valued biodefense applications. GRDG and Thompson are now focused on licensing their portfolio to larger pharmaceutical companies for down range development.[6]
Thompson's company GRDG works outside of government institutions and is exclusively focused on developing medical countermeasures that adhere to the principles and initiatives established by Project Bioshield, BARDA, and the Potomac Institute for Policy Studies.
Thompson is Director of Scientific Initiatives and a member of the Board of Directors of Interceptor Therapeutics, a partnership formed to develop and commercialize Daryl's technology. Interceptor Therapeutics includes former Assistant Surgeon General of the United States Dr. Roscoe M. Moore, Jr. as Senior Scientific Adviser.
Thompson was previously President of ATM Metabolics, LLC which specializes in the development of phyto-chemical pharmaceuticals aimed at preventing and reversing metabolic and neurological diseases.
Thompson was a founder, partner, and served as senior vice president and director of research at Solution Health Systems, Boca Raton, FL, from 2003 to 2006. During that time, his research focused on metabolic issues to solve the global diabetes epidemic.
In 2000, Thompson was recognized for designing a non-invasive glucose meter and received the Diabetes World Humanitarian Award from the Diabetes Research Center.
Thompson is co-author of three published scientific studies:
An upcoming documentary focused on engaging science-based adventure and educational nexus. The Bioquest follows the research team of GRDG as they explore unique locations around the world sharing exciting stories behind their biomedical discoveries focused on solutions to global health issues. This research is presented in a way that is both educational and entertaining.[9]
Daryl Thompson and GRDG are focused on licensing their technology portfolio to larger pharmaceutical companies and that process is underway. GRDG and Thompson have successfully introduced and coordinated the licenses of the Linebacker and Equivir technologies with Prophase laboratories.
A multi-faceted therapeutic platform for metabolic, neurologic, cancer, and infectious diseases[5] created to mirror the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker has demonstrated success against multiple disease categories including neurological, cancer, antiviral.[10] Linebacker has been licensed to Prophase Laboratories for down range development and distribution.[6]
A patented Over the Counter (OTC) medication successfully tested in vitro against Rhinovirus, Influenza, Cholera, SARS-CoV-2 (COVID-19) and in a Biosafety Level 4 facility, Ebola. Equivir/Nemovir is both a treatment and a prophylactic for COVID-19 and is moving to human clinical trials.[11] Equivir has been licensed to Prophase Laboratories for down range development and distribution.[6]
3F stands for “Functional Fragrance Formulation”. The 3F Biofragrance technologies is a suite of “functional fragrances” specifically designed for addition to consumer products such as cosmetics, detergents, and air fresheners to boost the products effectiveness or add additional protective properties. These properties include insect protection, antimicrobial, preservative, synergistic and healing capabilities.
The 3F Biofragrance is the product of a 3 year research project conducted on over 270 rare orchid scents from across the globe. The project yielded a vast library of compounds that cover wide variety of biological activities. These compounds, once cataloged and identified can be used to create unique and numerous bioactive formulas that mimic a pleasant smell.[12]
The 3F Antimicrobial formula has been tested and proven effective against a number of resistant pathogenic bacterial microorganisms such as E.coli, MRSA, Staph, C.albicans, Tuberculosis as well as numerous strains of problematic viruses including rhinovirus, influenza and SARS-COV2.[12]
3F Antimicrobial has proven to be synergistic with ethyl alcohol which translates into lower levels of alcohol required for formulation while also increasing the effectiveness against target microorganisms thus making a cleaner, safer and more effective sanitizer.[12]
The 3F DEET Booster is designed to work synergistically to increase effectiveness of insect repellency while also allowing for the reduction of DEET required within the formula. 3F DEET Booster improves overall protection and creates a superior product that has a pleasant and enjoyable scent with a much better feel to the skin.[12]
GRDG has done research to identify key compounds within the ghost orchid’s scent that have the ability to interact or block mosquito’s ability to detect humans as prey. They have since worked with these compounds to create functional scents that can block these receptors and make humans invisible to mosquitoes.[12]
A Sugar modification technology, designed as a solution to the growing global trend of Diabetes and Obesity. Our modified sugar is not only has 30% reduced carbohydrate but also actively reverse insulin resistance. Laetose solves the global Sugar and Salt Reduction Initiative.[13]
An improved form of the antihistamine Diphenhydramine with increased binding characteristics. Q-Diphen was designed specifically as a emerging SARS-COV2 prophylactic strategy.[14]
The solution to the Patent Cliff[15] accomplished by creating a new class of medicinal chemistry that uses advanced methods to increase effectiveness and persistence of natural compounds and existing drugs. The safety attributes of the original molecules are maintained. Typically, drug discovery processes modify functional groups. The Bioforge's new techniques alter the behavior of molecules at the sub-molecular level. GRDG estimates that 65% of the World Health Organization Essential Medicines List can be improved and re-patented using Bioforge and these methods can be used to enhance and patent natural compounds including many substances used in traditional medicines around the world.[16][17]
GRDG is working on advanced bio-compatible plastics that mitigate accumulation of plastics in oceans and landfills and also provide UVA and UVB protection for many types of material for including containers, hard surfaces, and fibers for clothing. The technology is presently in development and testing.
The bioplastics will have contain antimicrobial properties for consumer products that control the spread of active pathogens such as SARS-CoV-2, Influenza, E. coli, Staph, and Rhinovirus, by exploiting key strategies found in the biological realm. These new plastics are specifically focused on solutions for common products such as cups, plates, utensils, plastic bags, and countertops. The first prototypes are currently undergoing antimicrobial resistance testing.[18]
Thompson has successfully developed, patented, and/or marketed:
The Grapefruit Solution: Lower Your Cholesterol, Lose Weight and Achieve Optimal Health with Nature’s Wonder Fruit (LINX Corp., 2004), with M. Joseph Ahrens[30]
{{cite press release}}: |last= has generic name (help)